Atlas Trials

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Clinical trial NCT02037256 · COMPLETED

Trial details

NCT number
NCT02037256
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Adult Grade III Lymphomatoid GranulomatosisB-cell Chronic Lymphocytic LeukemiaContiguous Stage II Adult Burkitt LymphomaContiguous Stage II Adult Diffuse Large Cell LymphomaContiguous Stage II Adult Diffuse Mixed Cell LymphomaContiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaContiguous Stage II Adult Immunoblastic Large Cell LymphomaContiguous Stage II Adult Lymphoblastic LymphomaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular LymphomaContiguous Stage II Mantle Cell Lymphoma
Start date
2011-07-01
Primary completion
2015-01-21
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.